Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection

NCT04344600 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Single center study with low enrollment

Conditions

Sars-CoV-2 Infection

Interventions

DRUG: Peginterferon lambda alfa-1a subcutaneous injection
OTHER: Saline

Sponsor

Johns Hopkins University

Collaborators

[object Object]